Purpose: The primary aim of this study was to investigate volume effect and safety of up to 50 mL/kg BW 6% hydroxyethyl starch (HES) 130/0.4 in adult and pediatric patients undergoing major elective surgery. The need to infuse human albumin may be reduced or avoided in Japan if these large doses 6% HES 130/0.4 can be infused. Methods: The study was an uncontrolled, open-labeled, multi-center trial. Fifteen adult and 5 pediatric patients undergoing major elective surgery received 6% HES 130/0.4 (Voluven ® ) with a maximum dose of 50 mL/kg from the start of surgery until 2 hours after the end of surgery according to a treatment algorithm. The primary efficacy endpoint was the volume effect of 6% HES 130/0.4 determined by the volume of saved albumin during the investigational period and the time course of hemodynamic stability in adult and pediatric patients. Safety parameters were fluid balance, hemodynamic and laboratory parameters ECG, local and systemic tolerance and adverse events. Results: Adult patients received a mean of 32.0 mL/kg of 6% HES 130/0.4. For 12 out of 15 adult patients an average amount of 1033.8 mL (18.6 mL/kg) albumin could be saved. The other 3 adult patients did not receive more than 1000 mL of HES 130/0.4. All pediatric patients received approximately 50 mL/kg of HES 130/0.4; for these patients an average amount of 39.9 mL/kg body weight albumin could be saved. The majority of adult patients, and all pediatric patients were hemodynamically stable at all 3 time points. The observed changes of the assessed laboratory parameters including hematological and coagulation parameters or in any other safety parameter determined did not reveal any safety concern related to the administration of 6% HES 130/0.4 up to doses of 50 mL/kg body weight. Conclusion: The study results indicate that 6% HES 130/0.4 has a reliable volume effect, could contribute to significant human albumin savings and was safe and well tolerated up to a maximum dose of 50 mL/kg body weight in adult and pediatric patients undergoing major elective surgery.
Introduction
Colloid solutions are indicated for the treatment of hypovolemia and to maintain adequate circulating blood volume in patients undergoing surgery, experiencing trauma, or in intensive care. Among the available synthetic colloids, hydroxyethyl starch (HES) has been shown to have the lowest incidence of anaphylactoid reactions [1] . With the latest third generation, so called tetrastarches or HES 130/0.4, a major advancement particularly in respect of safety issues has been achieved over recent years. This advancement leads to a more rapid metabolization and degradation of HES molecules and thus to a minimal plasma accumulation even after repeated administration of HES 130/0.4 [2] . In addition, the influence on the coagulation system has been minimized [3] . Several studies confirmed that HES 130/0.4 does not result in deterioration in kidney function [4] in surgery even in those patients who are prone to acute renal failure [5] . Interestingly, despite the more rapid metabolization and the higher urinary excretion rate of HES 130/0.4 the duration of volume effect has been preserved comparable to that of pentastarches, such as HES 200/0.5 [6] .
The usage of the currently available HES 70/0.5 solution in Japan is limited to doses up to 20 mL/kg body weight (adult patients) or up to 10 mL/kg body weight (pediatric patients). In patients exceeding this dose limitation and requiring additional colloid loading, human albumin is recommended according to Japanese guidelines for transfusion (2007-revised 2005 guideline for usage of blood products by the Japanese Ministry of Health, Labor and Welfare). Consequently, the need to infuse human albumin may be reduced or avoided once the current dose limitation of HES 70/0.5 is reached if the infusion of larger volumes of HES 130/0.4 up to doses of 50 mL/kg BW would be possible in Japan like in most other countries worldwide. Consequently the reduction or avoidance of albumin infusions may also lead to considerable cost-savings.
Therefore, the aim of this study was to show the volume effect of 6% HES 130/0.4 and to demonstrate the safety of doses up to 50 mL/kg body weight in Japanese patients undergoing major elective surgery with an expected blood loss ≥ 1000 mL in adults and 15 mL/kg body weight in pediatric patients, respectively.
Materials and Methods

Study Design
In this prospective, uncontrolled, open-labeled, multicenter trial a total of 20 patients were screened and enrolled into the study. All 20 patients were treated with 6% HES 130/0.4 and analyzed for efficacy and safety variables. Inclusion criteria were patients undergoing major elective surgery, with an expected blood loss of ≥1000 mL in the case of adults (≥20 years of age) or ≥15 mL/kg (pediatric patients <20 years of age), a routine measurement of CVP (adult patients only) and a written informed consent and assent, if applicable. No restriction was placed on surgical procedures. Patients were excluded if they fulfilled the following exclusion criteria: participation in a clinical trial within the last 4 months from the day of administration of HES 130/0.4, known or suspected allergy to hydroxyethyl starch including its ingredients and related drugs, American Society of Anesthesiologists (ASA) classification ≥IV, (in the case of adults) renal failure with oliguria (<400 mL urine/24 hours) and anuria or (in the case of pediatric patients) renal failure with oliguria and anuria not related to hypovolemia, receiving dialysis treatment, known bleeding disorders, fluid overload, intracranial bleeding, severe hypernatremia, severe hyperchloremia, known pregnancy, ineligibility at the discretion of the investigator.
6% HES 130/0.4 (Voluven ® , Fresenius Kabi, Bad Homburg, Germany) was administered intravenously to maintain or restore hemodynamic parameters up to a maximum dose of 50 mL/kg body weight. Before skin incision, no colloid solutions were to be used. Following a treatment algorithm (Figure 1 ) HES 130/0.4 was administered during the investigational period with an infusion rate of 250 to 500 mL in about 15 to 30 minutes, from the start of surgery (skin incision) until 2 h (±15 min) after end of surgery. After reaching the dose limit of 50 mL/kg BW of HES 130/0.4, human albumin 4.4% or 5% was used exclusively as colloid in case the patient required additional colloids. In addition, a sufficient fluid therapy had to be administered as basic infusion of crystalloids .During the whole study period, transfusion requirements for blood products followed 2007-revised 2005 Guideline for usage of blood products by MHLW.
Investigations and Assessments
Hemodynamic stability was defined as a systolic blood pressure of not more than 30% below the baseline value and evaluated by end of surgery, 2 hours after surgery and 24 hours after surgery.
Systolic/diastolic blood pressure (SBP/DBP), mean arterial pressure (MAP), heart rate (HR) and central venous pressure (CVP, in adults and preferable in pediatric patients) were measured immediately before induction of anesthesia, in the case of adults, and the day before induction of anesthesia, in the case of pediatric patients, until 48 h after the end of surgery.
Fluid balance was determined by fluid input categorized as HES 130/0.4, 4.4% human albumin, 5% human albumin, commercial colloid, crystalloids, predeposit autologous blood, salvaged autologous blood, homologous packed red blood cells, fresh frozen plasma, platelets, and other minus fluid output categorized as urine output, blood loss [suction] , and blood loss [from clothweight calculation]).
Laboratory parameters were measured at baseline, at end of surgery as well as 2 and 24 hours after surgery, and also as last value available and included following parameters: hematology (hematocrit, hemoglobin, and platelets), serum clinical chemistry (creatinine, blood urea nitrogen (BUN), total bilirubin (only adult patients), glucose, total protein, albumin, sodium, potassium, chloride, GOT/AST, GPT/ALT, lactate dehydrogenase (LDH, only adult patients), γ-GT (only adult patients), and amylase), and hemostasis (international normalized ratio INR), activated partial thromboplastin time (aPTT), fi-( brinogen, factor VIII activity (only adult patients), and von Willebrand factor antigen (only adults patients).
ECG was determined until 24 hours after surgery. Local and systemic tolerance was evaluated as good, moderate or poor until 2 hours after surgery, and adverse events were followed-up for 28 days after surgery.
Statistics
The primary efficacy endpoint was the volume effect of 6% HES 130/0.4 determined by 1) the volume of the saved albumin during the investigational period and 2) the time course of hemodynamic stability stratified by adult and pediatric patients. Saved albumin was defined as the amount of HES 130/0.4 administered during the investigational period after 1000 mL for adults and 10 mL/kg for pediatric patients had been reached The definition was based on the assumption that 1 mL administered HES would save 1 mL human albumin that would have been used once the dose limit for HES had been Only descriptive methods were used. The variables were summarized by age (adult and pediatric patients) with the number of non-missing observations (n), arithmetic mean, standard deviation (SD), median and ranges. Changes from baseline were calculated and summarized by time point for all post-baseline values and the individually determined last available post-baseline value.
Results
Efficacy
Fifteen adult and 5 pediatric Japanese patients were assessed for both efficacy and safety. The demographic data for the adult and pediatric patient populations treated with HES 130/0.4 are shown in Table 1 , information on individual type and time of surgery and presented in Table 2 . Adult patients underwent different types of abdominal surgery, with a majority of patients undergoing liver surgery (7 patients). All pediatric patients were liver transplanted (living donor transplantation).
All patients received % HES 130/0.4. For 12 out of 15 adult patients an average amount of 1033.8 mL (18.6 ml/kg) albumin was saved, whereas 3 adult patients did not receive more than 1000 mL of 6% HES 130/0.4. All pediatric patients received about 50 mL/kg of HES 130/0.4; for these 5 pediatric patients a mean volume of 652.7 ml (39.9 mL/kg body weight) albumin was saved ( Table 3) .
The summary of hemodynamic stability is shown in Table 4 . Overall, the majority of adult patients and all pediatric patients were hemodynamically stable at all time points.
Safety
Fluid Input and Output
The data for fluid input and output are shown in Table 5 . When expressed in terms of mL/kg body weight, adult patients received a mean of 32.0 mL/kg of 6% HES 130/0.4. All pediatric patients received about 50 mL/kg 6% HES 130/0.4. Five adult patients and 3 pediatric patients required additional colloids for hemodynamic stabilization, which was 5% human albumin in all cases. Mean total input was 12,091 mL for the adult patients and 7584 mL for the pediatric patients. Total overall fluid output had a mean value of 7860 mL in adult patients and 5600 mL in the pediatric patients. Overall, fluid balance was positive in all patients. Tables 6-8 summarize the data for the laboratory pa- rameters monitored during the investigational period. Regarding hematology parameters ( Table 6 ) median values for hematocrit, hemoglobin, and platelets showed major decreases from baseline for adult and pediatric patients and were still below baseline values at 24 hours.
Laboratory Parameters
The analysis of hemostasis parameters ( Table 7) revealed increases of INR and aPTT for both patient groups, which was even stronger for pediatric than for adult patients. For adults, the strongest increase for both parameters occurred at the end of surgery followed by a decrease until 2 h after surgery whereas for pediatric patients the strongest increase was observed 2 hours after the end of surgery. In pediatric patients, values nearly returned to baseline level for the last available value.
Fibrinogen showed strong decreases in the median for both patient subgroups at the end of surgery and 2 hours later. For adult patients, the median decrease was less pronounced at 24 hours, while for pediatric patients there was still a major decrease at 24 hours which, however, returned to nearly the baseline level for the last available value.
Compared to baseline, Factor VIII activity was strongly decreased at the end of surgery, still slightly decreased 2 hours later and slightly increased at 24 hours. Von Willebrand factor antigen was strongly decreased at the end of surgery. The median values were nearly back to baseline values 2 hours after surgery and increased from baseline at 24 hours after surgery.
The analysis of clinical chemistry parameters indicated that median creatinine and BUN values basically remained stable from baseline to the end of surgery and at 24 hours for adult and pediatric patients. Total bilirubin was nearly unchanged at the end of surgery and increased at 24 hours. Glucose showed increases in the median for adult patients and stronger increases for pediatric patients after surgery. Median total protein and albumin showed decreases for each patient group at all post-baseline time points. In pediatric patients, the decrease was smaller for the last available value. Sodium and potassium showed only small median changes in adults. Transiently, there was a significant increase in sodium in pediatric patients 2 hours after end of surgery. Median chloride increased at the end of surgery (adult patients) and 2 hours after end of surgery (pediatric patients), and returned close to the baseline values at 24 hours. Both GOT/AST and GPT/ALT showed strong median increases after surgery, in particular in pediatric patients with very high median values for GOT/AST and GPT/ALT two hours post-surgery and the next 24 h. This observation should be regarded in the context that all pediatric patients had a liver transplantation and an increase of transaminases may be seen as a normal physiological adaptation after surgery. For the last available value, which includes additional follow-up measureements, GOT/AST and GPT/ALT levels of the transplanted livers were within the normal ranges in pediatric patients. Seven adult patients underwent a liver surgery during this study. Due to the type of surgery, high GOT/AST and GPT/ALT values occurred particularly in these patients, as well as in two patients with pancreaticoduodenectomy. Median LDH (only adult patients) slightly increased at the end of surgery and more pronounced at 24 hours. Median γ-GT (only adult patients) decreased at the end of surgery, whereas the values were slightly increased at 24 hours. Median value of amylase was nearly unchanged at the end of surgery. Thereafter it strongly increased in both patient groups, mainly at 24 hours and decreased thereafter. Overall, the analyzed laboratory parameters did not reveal any safety concern with regard to the administration HES 130/0.4.
The analysis of ECG parameters did not reveal important changes and local and systemic tolerance of HES 130/0.4 was always assessed as good (data not shown).
Adverse Events
No adverse event led to discontinuation of the administration of 6% HES 130/0.4. The most frequent reported adverse event for adults was "blood amylase increased", which occurred in all 7 adult patients with adverse events related to the study medication and is an established and well-known effect of the administration of starches. In pediatric patients, the most common reported adverse event was an abnormality in serum electrolytes. All 5 pediatric patients had an increased blood chloride level, 4 patients had abnormal or increased sodium levels, and 2 patients had increased blood amylase. None of these adverse events was serious. One adult patient died 12 days after surgery, but the death was assessed as being unrelated to the administration of 6% HES 130/0.4.
Discussion
In this study, the infusion of high volumes of up to 50 mL/kg BW of 6% HES 130/0.4 was shown to be efficacious and safe in adult and pediatric patients undergoing major elective surgery. Based on the obtained findings it is assumed that considerable potential savings of human albumin are possible if the internationally approved maximum dose of 50 mL/kg BW of 6% HES 130/0.4 would also be possible in Japan. For 12 of the 15 adult patients in need of additional colloid solution, approximately 1000 mL albumin could be saved, and about 650 mL in pediatric patients.
In the present study the savings of human albumin are based on the assumption that 6% HES 130/0.4 and 5% human albumin have the same volume effect in adults and children. Comparable efficacy of both colloids has been previously demonstrated in several studies among different age groups of patients and clinical settings. In a study by Standl et al. (2008) [7] comparable volumes of 6% HES 130/0.4 and 5% human albumin were infused in 82 small infants (<2 years) undergoing non-cardiac surgery to restore or maintain hemodynamic stabilization. Hanart et al. (2009) [8] compared the effects of 6% HES 130/0.4 and 4% human albumin on perioperative blood loss and intraoperative volume requirements in 119 pediatric patients undergoing cardiac surgery. Both groups received comparable high volumes of both colloids (50 ml/kg), and measured or calculated blood losses were similar between both groups. A recent study [9] con-
